Latest News
NMD Pharma Releases Community Letter Regarding Phase 2 SYNAPSE-SMA Clinical Trial
NMD Pharma recently shared exciting news with the SMA community: the last participant has completed their part in the SYNAPSE-SMA Phase 2 clinical trial, testing ignaseclant (formerly known as NMD670), […]
Meet the Scientists Behind SMA Research and Discover What’s Coming Next
The Family-Friendly Poster Session is one of the most anticipated events at the Annual SMA Conference! This year’s session will be held on Friday, June 26, from 6:30 pm to […]
Cure SMA Releases Updated Combination Therapy Booklet and New Video on Muscle-Directed Therapy
As more SMA treatments become available, people living with SMA, their families, and caregivers are asking new questions about how treatments work, whether using more than one treatment could help, […]
Cure SMA Shares Research Insights with Scientists and Clinicians at Spring 2026 Conferences
Cure SMA is pleased to announce the participation of our Research Department staff in the following conferences: 2026 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference (March 8 – […]
Cure SMA Releases the 2025 Annual State of SMA Report
Cure SMA is pleased to announce the publication of the 5th annual State of SMA report. Drawing on data collected by Cure SMA through 2025, this report features insights into […]
FDA Accepts Scholar Rock’s Biologics License Application (BLA) to Review Apitegromab for SMA
Today, Scholar Rock shared that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for apitegromab, an investigational treatment for spinal muscular atrophy (SMA), with a […]